Lion Point Capital
Latest statistics and disclosures from Lion Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CUE, PRAX, MLTX, FENC, RPRX, and represent 32.92% of Lion Point Capital's stock portfolio.
- Added to shares of these 1 stock: CUE.
- Started 1 new stock position in CUE.
- Reduced shares in these 1 stock: Cue Biopharma.
- Sold out of its position in Cue Biopharma.
- Lion Point Capital was a net buyer of stock by $1.2M.
- Lion Point Capital has $21M in assets under management (AUM), dropping by 24.94%.
- Central Index Key (CIK): 0001643354
Tip: Access up to 7 years of quarterly data
Positions held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Lion Point Capital
Lion Point Capital holds 35 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cue Biopharma (CUE) | 8.0 | $1.7M | NEW | 53k | 31.56 |
|
| Praxis Precision Medicines I Com New (PRAX) | 7.1 | $1.5M | 4.5k | 334.79 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 6.3 | $1.3M | 68k | 19.47 |
|
|
| Fennec Pharmaceuticals (FENC) | 5.8 | $1.2M | 112k | 10.75 |
|
|
| Royalty Pharma Shs Class A (RPRX) | 5.7 | $1.2M | 21k | 56.07 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 5.4 | $1.1M | 80k | 14.15 |
|
|
| Milestone Pharmaceuticals (MIST) | 5.3 | $1.1M | 820k | 1.34 |
|
|
| Benitec Biopharma Com New (BNTC) | 4.0 | $830k | 62k | 13.38 |
|
|
| Syndax Pharmaceuticals (SNDX) | 3.8 | $787k | 36k | 21.86 |
|
|
| Biohaven (BHVN) | 3.7 | $769k | 52k | 14.88 |
|
|
| Geron Corporation (GERN) | 3.5 | $740k | 578k | 1.28 |
|
|
| Uniqure Nv SHS (QURE) | 3.2 | $677k | 15k | 46.06 |
|
|
| Ardelyx (ARDX) | 3.1 | $656k | 129k | 5.10 |
|
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 2.9 | $610k | 5.5k | 110.94 |
|
|
| Disc Medicine (IRON) | 2.8 | $592k | 8.1k | 73.14 |
|
|
| Sarepta Therapeutics (SRPT) | 2.4 | $512k | 29k | 17.97 |
|
|
| Humacyte (HUMA) | 2.4 | $507k | 650k | 0.78 |
|
|
| Kura Oncology (KURA) | 2.4 | $505k | 46k | 10.97 |
|
|
| Viatris (VTRS) | 2.1 | $440k | 28k | 15.88 |
|
|
| Dyne Therapeutics (DYN) | 1.9 | $400k | 18k | 22.21 |
|
|
| Bridgebio Pharma (BBIO) | 1.8 | $372k | 5.0k | 74.48 |
|
|
| Edgewise Therapeutics (EWTX) | 1.8 | $370k | 9.1k | 40.63 |
|
|
| Pacira Pharmaceuticals (PCRX) | 1.6 | $343k | 14k | 25.37 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 1.5 | $319k | 27k | 11.98 |
|
|
| Rocket Pharmaceuticals (RCKT) | 1.4 | $294k | 86k | 3.42 |
|
|
| Janux Therapeutics (JANX) | 1.4 | $292k | 19k | 15.36 |
|
|
| Mineralys Therapeutics (MLYS) | 1.4 | $283k | 11k | 26.98 |
|
|
| Gh Research Ordinary Shares (GHRS) | 1.3 | $274k | 10k | 26.88 |
|
|
| Seres Therapeutics Com New (MCRB) | 1.2 | $249k | 32k | 7.89 |
|
|
| Brooks Automation (AZTA) | 1.2 | $248k | 9.7k | 25.52 |
|
|
| Jasper Therapeutics Com New (JSPR) | 0.9 | $196k | 465k | 0.42 |
|
|
| Innoviva (INVA) | 0.9 | $186k | 8.2k | 22.71 |
|
|
| Innate Pharma S A Sponsored Ads (IPHA) | 0.7 | $149k | 81k | 1.84 |
|
|
| Arcutis Biotherapeutics (ARQT) | 0.7 | $138k | 5.3k | 26.22 |
|
|
| Spruce Biosciences Com New (SPRB) | 0.3 | $54k | 1.0k | 54.00 |
|
Past Filings by Lion Point Capital
SEC 13F filings are viewable for Lion Point Capital going back to 2015
- Lion Point Capital 2026 Q2 filed Aug. 14, 2026
- Lion Point Capital 2026 Q1 filed May 15, 2026
- Lion Point Capital 2025 Q4 filed Feb. 17, 2026
- Lion Point Capital 2025 Q3 filed Nov. 14, 2025
- Lion Point Capital 2025 Q2 filed Aug. 14, 2025
- Lion Point Capital 2025 Q1 filed May 15, 2025
- Lion Point Capital 2024 Q4 filed Feb. 14, 2025
- Lion Point Capital 2024 Q3 filed Nov. 14, 2024
- Lion Point Capital 2024 Q2 filed Aug. 14, 2024
- Lion Point Capital 2024 Q1 filed May 15, 2024
- Lion Point Capital 2023 Q4 filed Feb. 14, 2024
- Lion Point Capital 2023 Q3 filed Nov. 14, 2023
- Lion Point Capital 2023 Q2 filed Aug. 14, 2023
- Lion Point Capital 2023 Q1 filed May 15, 2023
- Lion Point Capital 2022 Q4 filed Feb. 14, 2023
- Lion Point Capital 2022 Q3 filed Nov. 14, 2022